ClinicalTrials.gg
CompletedNCT00865904Updated Aug 28, 2015Results posted

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

A Phase 2 interventional study of VX-809 and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-28.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
8th of 20
93 · median 66
Started
2009
with 1 other
Phase 2
4 of 20
none open now
Registered
1st of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 8th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 2, and was the 1st registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

The primary objective of the study was to evaluate the safety and tolerability of VX-809 in participants with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.

Read the detailed description

This was a Phase 2, randomized, double-blind, placebo-controlled, multiple-dose study of orally-administered VX-809 in participants with CF who are homozygous for the specific CFTR mutation known as ∆F508 or F508del. Enrollment was planned for 90 participants at approximately 20 centers. Participants were planned to be randomized in a 4:1 ratio to receive 1 of 4 doses of VX-809 or placebo once a day for 28 days in a parallel design. Participants were outpatients during the study, except for overnight stays on Day 1 and 28.

03

Conditions studied

  • Cystic Fibrosis

Keywords

  • ∆F508
  • F508del
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • CFTR
  • Pancreatic diseases
  • Lung diseases
  • Genetic disease, inborn
  • Infant, newborn, diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CF with ∆F508-CFTR mutation in both alleles
  • (FEV1) greater than or equal to (>=) 40 percent (%) of predicted normal for age, gender, and height
  • Weight >=40 kilograms (kg) and greater than or equal to 18.5 kilogram per square meter (kg/m\^2)
  • Screening laboratory values, tests, and physical examination within acceptable ranges
  • Negative pregnancy test (for women of )
  • Able and willing to follow requirements
  • Willing to remain on a stable medication regimen for the duration of study participation

Exclusion criteria

Exclusion Criteria:

  • History of any illness, or any ongoing acute illness, that could impact the safety of the study participant or may confound results of study
  • Pulmonary exacerbation or changes in therapy for pulmonary disease within 14 days before receiving the first dose of study drug
  • Impaired hepatic or renal function
  • History of organ or hematological transplant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
93 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo matched to VX-809 capsule orally once daily for 28 days.

    Drug: Placebo

  • Experimental
    VX-809, 25 mg

    VX-809, 25 milligram (mg) capsule orally once daily for 28 days.

    Drug: VX-809

  • Experimental
    VX-809, 50 mg

    VX-809, 50 mg capsule orally once daily for 28 days.

    Drug: VX-809

  • Experimental
    VX-809, 100 mg

    VX-809, 100 mg capsule orally once daily for 28 days.

    Drug: VX-809

  • Experimental
    VX-809, 200 mg

    VX-809, 200 mg capsule orally once daily for 28 days.

    Drug: VX-809

Interventions

  • DrugVX-809

    Capsules

  • DrugPlacebo

    Placebo matched to VX-809 capsules.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability Based on Adverse Events (AEs)

    AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. Serious adverse event (SAE) (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Number of participants with AEs and SAEs are reported. An AE that started at or after initial dosing of study drug, or increased in severity after initial dosing of study drug visit is considered treatment-emergent.

    Time frame: Up to 14 days after last dose (last dose = Day 28)

Secondary outcomes

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Day 28

  2. Change From Baseline in Percent Predicted FEV1 at Day 28

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Predicted FEV1 (for age, gender, and height) was calculated using the Knudson method.

    Time frame: Baseline, Day 28

  3. Change From Baseline in Forced Vital Capacity (FVC) at Day 28

    FVC is the volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.

    Time frame: Baseline, Day 28

  4. Change From Baseline in Forced Expiratory Flow Over the Middle Half of the FVC (FEF25-75) at Day 28

    FEF25-75 is total volume of air exhaled from the lungs over the middle half of the FVC test, expressed as liters per second (L/sec).

    Time frame: Baseline, Day 28

  5. Change From Baseline in Sweat Chloride at Day 28

    Sweat samples were collected using an approved Macroduct (Wescor) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride.

    Time frame: Baseline, Day 28

  6. Change From Baseline in Nasal Potential Difference (NPD) of Zero Chloride Plus Isoproterenol Response at Day 28

    Nasal potential difference (NPD) provides a direct and sensitive evaluation of sodium and chloride transport in secretory epithelial cells via assessment of transepithelial bioelectric properties. NPD under conditions of zero chloride concentration perfusion solution in the presence of isoproterenol is reported. NPDs were performed according to Cystic Fibrosis Foundation Therapeutics Development Network (CFFT TDN) Standard Operating Procedure (SOP) 528.00 "Standardization of Measurement of Nasal Membrane Transepithelial Potential Difference (NPD) - electronic data capture (EDC) and Perfusion or Perfusion-Free Probe".

    Time frame: Baseline, Day 28

  7. Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Domain Scores at Day 28

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. CFQ-R domains include: Body, Digestion, Eat, Emotion, Health Perceptions, Physical, Respiratory, Role, Social, Treatment Burden, Vitality, and Weight. Individual domain score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Day 28

  8. Maximum Plasma Concentration (Cmax) of VX-809

    Only participants who received VX-809 were analyzed for this outcome measure.

    Time frame: Day 1 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, and 24 hours post-dose), Day 28 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, 24, and 30-60 hours post dose)

  9. Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of VX-809

    Only participants who received VX-809 were analyzed for this outcome measure.

    Time frame: Day 1 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, and 24 hours post-dose), Day 28 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, and 24 hours post dose)

07

Results

Posted Aug 28, 2015

Participant flow

Participant flow — Overall Study
MilestonePlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Started1918181820
Completed1718181719
Not completed20011
Withdrew: Randomized but not treated20011

Outcome measures

PrimarySafety and Tolerability Based on Adverse Events (AEs)

AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. Serious adverse event (SAE) (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Number of participants with AEs and SAEs are reported. An AE that started at or after initial dosing of study drug, or increased in severity after initial dosing of study drug visit is considered treatment-emergent.

Time frame:
Up to 14 days after last dose (last dose = Day 28)
Reported as:
Number · participants
Safety and Tolerability Based on Adverse Events (AEs)
participantsPlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Participants With Any AE1716151618
Participants With SAE15103
SecondaryChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Day 28
Reported as:
Least squares mean · liters
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28
litersPlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 280.029 (-0.0823 to 0.1398)-0.049 (-0.1578 to 0.0588)-0.031 (-0.1401 to 0.0787)0.015 (-0.0972 to 0.1263)-0.009 (-0.1146 to 0.0970)
SecondaryChange From Baseline in Percent Predicted FEV1 at Day 28

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Predicted FEV1 (for age, gender, and height) was calculated using the Knudson method.

Time frame:
Baseline, Day 28
Reported as:
Least squares mean · Percent predicted of FEV1
Change From Baseline in Percent Predicted FEV1 at Day 28
Percent predicted of FEV1PlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Change From Baseline in Percent Predicted FEV1 at Day 280.285 (-2.8268 to 3.3973)-1.637 (-4.6836 to 1.4089)-0.375 (-3.4540 to 2.7046)0.168 (-2.9653 to 3.3011)-0.165 (-3.1346 to 2.8044)
SecondaryChange From Baseline in Forced Vital Capacity (FVC) at Day 28

FVC is the volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.

Time frame:
Baseline, Day 28
Reported as:
Mean · liters
Change From Baseline in Forced Vital Capacity (FVC) at Day 28
litersPlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Change From Baseline in Forced Vital Capacity (FVC) at Day 280.085 ± 0.2857-0.055 ± 0.2331-0.020 ± 0.3494-0.004 ± 0.1916-0.023 ± 0.3668
SecondaryChange From Baseline in Forced Expiratory Flow Over the Middle Half of the FVC (FEF25-75) at Day 28

FEF25-75 is total volume of air exhaled from the lungs over the middle half of the FVC test, expressed as liters per second (L/sec).

Time frame:
Baseline, Day 28
Reported as:
Mean · liters per second (L/sec)
Change From Baseline in Forced Expiratory Flow Over the Middle Half of the FVC (FEF25-75) at Day 28
liters per second (L/sec)PlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Change From Baseline in Forced Expiratory Flow Over the Middle Half of the FVC (FEF25-75) at Day 28-0.030 ± 0.1730-0.011 ± 0.3231-0.029 ± 0.43730.045 ± 0.2702-0.052 ± 0.3558
SecondaryChange From Baseline in Sweat Chloride at Day 28

Sweat samples were collected using an approved Macroduct (Wescor) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride.

Time frame:
Baseline, Day 28
Reported as:
Least squares mean · millimole per liter (mmol/L)
Change From Baseline in Sweat Chloride at Day 28
millimole per liter (mmol/L)PlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Change From Baseline in Sweat Chloride at Day 280.84 (-3.493 to 5.166)0.93 (-3.308 to 5.173)-3.77 (-7.966 to 0.416)-5.29 (-9.618 to -0.963)-7.38 (-11.590 to -3.166)
SecondaryChange From Baseline in Nasal Potential Difference (NPD) of Zero Chloride Plus Isoproterenol Response at Day 28

Nasal potential difference (NPD) provides a direct and sensitive evaluation of sodium and chloride transport in secretory epithelial cells via assessment of transepithelial bioelectric properties. NPD under conditions of zero chloride concentration perfusion solution in the presence of isoproterenol is reported. NPDs were performed according to Cystic Fibrosis Foundation Therapeutics Development Network (CFFT TDN) Standard Operating Procedure (SOP) 528.00 "Standardization of Measurement of Nasal Membrane Transepithelial Potential Difference (NPD) - electronic data capture (EDC) and Perfusion or Perfusion-Free Probe".

Time frame:
Baseline, Day 28
Reported as:
Least squares mean · millivolts (mV)
Change From Baseline in Nasal Potential Difference (NPD) of Zero Chloride Plus Isoproterenol Response at Day 28
millivolts (mV)PlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Change From Baseline in Nasal Potential Difference (NPD) of Zero Chloride Plus Isoproterenol Response at Day 28-1.017 (-3.2979 to 1.2637)0.832 (-1.1302 to 2.7943)0.142 (-2.0369 to 2.3208)1.382 (-0.9853 to 3.7491)1.583 (-0.6952 to 3.8612)
SecondaryChange From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Domain Scores at Day 28

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. CFQ-R domains include: Body, Digestion, Eat, Emotion, Health Perceptions, Physical, Respiratory, Role, Social, Treatment Burden, Vitality, and Weight. Individual domain score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Day 28
Reported as:
Least squares mean · units on a scale
Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Domain Scores at Day 28
units on a scalePlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Body-1.341 (-6.4183 to 3.7370)-0.206 (-5.2276 to 4.8151)-1.626 (-6.6796 to 3.4276)2.611 (-2.5525 to 7.7746)0.058 (-4.8954 to 5.0123)
Digestion4.620 (-0.2530 to 9.4935)2.284 (-2.4928 to 7.0605)-0.719 (-5.5599 to 4.1216)0.251 (-4.6794 to 5.1810)2.578 (-2.1027 to 7.2580)
Eat2.110 (-3.9925 to 8.2128)-3.662 (-9.6704 to 2.3463)-7.269 (-13.3216 to -1.2161)3.242 (-3.0242 to 9.5087)-2.576 (-8.4313 to 3.2793)
Emotion4.859 (-0.4200 to 10.1372)-3.222 (-8.4312 to 1.9866)-1.358 (-6.5817 to 3.8666)3.489 (-1.9312 to 8.9087)-2.624 (-7.7058 to 2.4585)
Health Perceptions5.034 (-1.6041 to 11.6713)-2.839 (-9.2912 to 3.6131)-6.967 (-13.4203 to -0.5137)-0.435 (-7.0778 to 6.2074)-1.896 (-8.3524 to 4.5604)
Physical1.225 (-5.3271 to 7.7764)-5.968 (-12.3586 to 0.4217)-7.384 (-13.8167 to -0.9508)-3.464 (-10.0613 to 3.1335)-0.976 (-7.2596 to 5.3067)
Respiratory4.534 (-1.6158 to 10.6842)-5.223 (-11.2414 to 0.7956)-6.324 (-12.3453 to -0.3026)-1.290 (-7.5407 to 4.9598)2.215 (-3.6610 to 8.0901)
Role2.210 (-3.2279 to 7.6481)-5.941 (-11.3247 to -0.5577)-4.599 (-9.9912 to 0.7925)1.097 (-4.4579 to 6.6510)-6.533 (-11.7858 to -1.2803)
Social-0.554 (-4.8235 to 3.7152)-0.001 (-4.2221 to 4.2200)-1.013 (-5.2372 to 3.2122)0.469 (-3.8898 to 4.8273)-2.640 (-6.7802 to 1.5008)
Treatment Burden2.463 (-3.1916 to 8.1169)4.185 (-1.4220 to 9.7914)-5.962 (-11.5712 to -0.3530)1.421 (-4.3528 to 7.1954)-0.676 (-6.1363 to 4.7843)
Vitality-2.178 (-8.8193 to 4.4629)-4.645 (-11.1048 to 1.8139)-7.227 (-13.6961 to -0.7589)-1.516 (-8.1800 to 5.1472)0.730 (-5.5932 to 7.0522)
Weight0.304 (-9.4460 to 10.0543)5.410 (-4.2393 to 15.0600)2.175 (-7.5500 to 11.8997)8.827 (-1.1524 to 18.8063)-4.186 (-13.5956 to 5.2233)
SecondaryMaximum Plasma Concentration (Cmax) of VX-809

Only participants who received VX-809 were analyzed for this outcome measure.

Time frame:
Day 1 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, and 24 hours post-dose), Day 28 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, 24, and 30-60 hours post dose)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of VX-809
nanogram per milliliter (ng/mL)VX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Day 1 (n= 18, 18, 17, 19)760 ± 2801850 ± 6972930 ± 9166410 ± 2550
Day 28 (n= 17, 17, 16, 18)1100 ± 4432660 ± 10104620 ± 184010300 ± 4490
SecondaryArea Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of VX-809

Only participants who received VX-809 were analyzed for this outcome measure.

Time frame:
Day 1 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, and 24 hours post-dose), Day 28 (pre dose, 0.75, 1.5, 3, 4, 6, 9, 12, and 24 hours post dose)
Reported as:
Mean · hour*nanogram per milliliter (hr*ng/mL)
Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of VX-809
hour*nanogram per milliliter (hr*ng/mL)VX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Day 1 (n= 18, 18, 17, 19)7190 ± 219016600 ± 629029000 ± 1140059500 ± 26400
Day 28 (n= 17, 17, 16, 18)12900 ± 492028800 ± 1310054100 ± 31600119000 ± 73700

Adverse events

Collected over Up to 14 days after last dose (last dose = Day 28). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/17 (5.9%)17/17 (100%)
VX-809, 25 mg—5/18 (27.8%)16/18 (88.9%)
VX-809, 50 mg—1/18 (5.6%)15/18 (83.3%)
VX-809, 100 mg—0/17 (0%)16/17 (94.1%)
VX-809, 200 mg—3/19 (15.8%)18/19 (94.7%)
Most frequent serious events
Most frequent serious events
EventPlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
Cystic fibrosis lungCongenital, familial and genetic disorders1/174/181/180/173/19
HaemoptysisRespiratory, thoracic and mediastinal disorders0/171/180/180/170/19
Most frequent other events
Showing 10 of 145
Most frequent other events
EventPlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mg
CoughRespiratory, thoracic and mediastinal disorders7/1710/186/187/1710/19
RalesRespiratory, thoracic and mediastinal disorders1/176/182/183/173/19
Productive coughRespiratory, thoracic and mediastinal disorders3/172/180/184/176/19
DyspnoeaRespiratory, thoracic and mediastinal disorders1/175/183/182/174/19
HeadacheNervous system disorders3/174/185/182/175/19
PyrexiaGeneral disorders2/172/181/181/175/19
WheezingRespiratory, thoracic and mediastinal disorders3/171/184/181/170/19
Respiration abnormalRespiratory, thoracic and mediastinal disorders0/171/181/180/174/19
Nasal congestionRespiratory, thoracic and mediastinal disorders3/172/181/182/172/19
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/170/183/180/172/19

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mgTotal
Mean31.5 ± 9.3527.7 ± 8.9827.1 ± 8.2030.1 ± 11.5526.7 ± 6.8228.6 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVX-809, 25 mgVX-809, 50 mgVX-809, 100 mgVX-809, 200 mgTotal
Female6995736
Male1199121253
08

Study locations

25 sites
  • Birmingham, Alabama, United States
  • Palo Alto, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • St. Louis, Missouri, United States
  • Chapel Hill, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Seattle, Washington, United States
  • Brussels, Belgium
  • Leuven, Belgium
  • Toronto, Ontario, Canada
  • Cologne, Germany
  • Hannover, Germany
  • Rotterdam, Netherlands
  • Utrecht, Netherlands
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗
  • Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordonez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8. PubMed 21825083 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 5 years 8 months after primary completion. A results delay was requested in Mar 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2009
First posted
Mar 19, 2009
Start
Mar 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results delay requested
Mar 23, 2011
Results first posted
Aug 28, 2015
Last update
Aug 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00865904
Responsible party
Sponsor
First posted
Mar 19, 2009
Start date
Mar 2009
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Aug 28, 2015
Last update
Aug 28, 2015

Study contacts

Medical Monitor
study director · Vertex Pharmaceuticals Incorporated

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumacaftor

Start the discussion